Therapeutic antibody development company Patrys Limited (ASX: PAB) has appointed Dr. Rebecca Tunstall as Vice President, Corporate Development.
Reporting to CEO, Dr. Tunstall will be a key member of the executive team focusing on preparations for Patrys’ deoxymab clinical trials as well as broader executive functions.
Dr. Tunstall, who will commence with the company on May 16, 2022 has extensive experience in pharmaceutical clinical development and external engagement and is passionate about the development of medicines to improve human health.
She spent 13 years with GlaxoSmithKline (GSK) Australia in various leadership positions, predominantly in the clinical research department, focusing on oncology research and development.
Dr. Tunstall served as Head of Study Management for her final three years at GSK where she was responsible for the execution and delivery of all clinical trials in Australia, and was the primary contact for GSK’s Oncology Clinical and Translational Consortium.
Most recently, Dr. Tunstall was Senior Director of Stakeholder Engagement at MTPConnect, developing and driving the engagement and implementation plan for stakeholders and strategic partnerships within Australia’s medical technologies and pharmaceutical sector. In this role Dr. Tunstall built and maintained strong relationships with industry, governments, regulators, and research institutions across Australia and internationally.
Dr. Tunstall holds a Doctor of Philosophy from Deakin University and completed Post-Doctoral research at McMaster University and University of Guelph in Canada before returning to Australia and commencing work at GSK.
This is an important and exciting appointment for Patrys as we prepare for the first in human studies of PATDX1 in mid 2023, ideally followed by other deoxymab assets,” Patrys CEO and Managing Director, Dr. James Campbell, said.
“We are delighted to have been able to attract Rebecca to Patrys, and will benefit greatly from her experience and insights as we approach the clinic.
“Rebecca’s role will also encompass a range of corporate activities as Patrys builds a strong platform for growth in the coming year. Rebecca’s drive, experience, intellect and enthusiasm make her a perfect fit for the Patrys team and we are delighted to welcome her into the xompany.”
Dr. Tunstall said the Patrys team had made great advances with the deoxymab technology, which has the potential for broad use across a range of therapeutic indications ranging from brain cancer through to pancreatic cancer and triple negative breast cancer.
“I look forward to driving both the clinical development programme and a range of corporate activities as we establish Patrys as a leading Australian biotechnology company.”